Salah F, Demerdash Z, Shaker Z, El Bassiouny A, El Attar G, Ismail S, Badir N, El Din A S, Mansour M
Department of Immunology, Theodor Bilharz Research Institute, Warak El Hadar, Imbaba, Guiza, Cairo, Egypt.
Parasitol Res. 2000 Jan;86(1):74-80. doi: 10.1007/s004360050014.
A monoclonal antibody (mAb), 2F/11F, raised against Schistosoma haematobium soluble egg antigen (SEA) was found to be nonreactive with S. mansoni SEA or other parasite antigens (Fasciola hepatica, Echinococcus granulosus). This IgG1 mAb recognized a repetitive epitope on S. haematobium SEA in the molecular-weight regions of 70, 42, and 35 kDa. It was employed as both an antigen-capture and a biotinylated detection antibody in a sandwich enzyme-linked immunosorbent assay (ELISA) for the detection of circulating schistosome antigen (CSA) and had a detection limit of <1 ng S. haematobium SEA/ml. CSA levels were measured in serum and urine samples from 116 S. haematobium-infected rural students before therapy and at 4, 8, and 12 weeks after praziquantel treatment. Serum and urine samples from 50 S. mansoni -infected patients, 15 patients harboring other parasites, and 30 noninfected individuals were also assessed. CSA was detected in 90.5% of serum samples and 94% of urine samples from S. haematobium-infected patients. CSA was undetectable in serum from the 15 patients harboring other parasites and in 94% of serum samples and 84% of urine samples from S. mansoni-infected patients. In the S. haematobium-infected group a positive correlation was detected between CSA levels in serum and urine samples and the egg load per 10 ml urine. A significant reduction in CSA levels was detected in serum and urine samples after praziquantel therapy. CSA was undetectable in 87% of serum samples and 81.5% of urine samples from schistosomiasis haematobium patients at 12 weeks post-treatment. These data demonstrate that the use of mAb 2F/11F for detection of CSA provides a sensitive method for the immunodiagnosis and monitoring of cure of schistosomiasis haematobium.
一种针对埃及血吸虫可溶性虫卵抗原（SEA）产生的单克隆抗体（mAb）2F/11F，被发现与曼氏血吸虫SEA或其他寄生虫抗原（肝片吸虫、细粒棘球绦虫）无反应。这种IgG1单克隆抗体识别埃及血吸虫SEA上分子量为70、42和35 kDa区域的一个重复表位。它在夹心酶联免疫吸附测定（ELISA）中既用作抗原捕获抗体，也用作生物素化检测抗体，用于检测循环血吸虫抗原（CSA），检测限<1 ng埃及血吸虫SEA/ml。对116名感染埃及血吸虫的农村学生治疗前以及吡喹酮治疗后4周、8周和12周的血清和尿液样本中的CSA水平进行了测量。还评估了50名感染曼氏血吸虫患者、15名感染其他寄生虫患者和30名未感染个体的血清和尿液样本。在感染埃及血吸虫患者的90.5%血清样本和94%尿液样本中检测到CSA。在15名感染其他寄生虫患者的血清中未检测到CSA，在感染曼氏血吸虫患者的94%血清样本和84%尿液样本中也未检测到CSA。在感染埃及血吸虫的组中，血清和尿液样本中的CSA水平与每10 ml尿液中的虫卵负荷之间存在正相关。吡喹酮治疗后，血清和尿液样本中的CSA水平显著降低。治疗后12周，埃及血吸虫病患者87%的血清样本和81.5%的尿液样本中未检测到CSA。这些数据表明，使用单克隆抗体2F/11F检测CSA为埃及血吸虫病的免疫诊断和治愈监测提供了一种灵敏的方法。
